EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT

Fujian Lu, Zexuan Wu, Shaopeng Chi, Jiajin Li, Anna Ponek, Carter Liou, Qing Ma, Durgesh Bonde, Nikoleta Pavlaki, Mason E Sweat, Sanam Shafaattalab, Yashasvi Tharani und 3 weitere

Molecular Therapy · 2026-08 · 34 (8) · 4502-4517

DOI: 10.1016/j.ymthe.2026.04.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-08. Verfasst von Fujian Lu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: fujianlu@fudan.edu.cn. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Myocytes, Cardiac, Tachycardia, Ventricular, Carrier Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute, American Heart Association Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia caused by pathogenic variants in RYR2 that increase its diastolic Ca 2+ release. Current standard of care is insufficient to protect patients from ventricular tachycardia (VT) and sudden death. We identified RYR2 interaction with a subset of MYBPC3 in cardiomyocytes, and validated this interaction by immunostaining, proximity ligation assay, and co-immunoprecipitation. Adeno-associated virus serotype 9 (AAV9)-mediated MYBPC3 overexpression reduced VT in Ryr2 R176Q/+ mice, a model of CPVT. We identified a C-terminal fragment of MYBPC3, C6C10Δ, that is sufficient for RYR2 interaction and anti-arrhythmic activity. Recombinant C6C10Δ reduced the open probability of RYR2-R176Q channels in lipid bilayer single channel recordings, and virally delivered C6C10Δ reduced VT inducibility and duration in the CPVT mouse model and in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) harboring several different CPVT-causing RYR2 variants. In wild-type mice, MyoAAV4E-C6C10Δ did not detectably affect cardiac morphology or systolic function. However, a proportion of MyoAAV4E-C6C10Δ-treated wild-type mice exhibited inducible VT, suggesting proarrhythmic potential that warrants further study. Together, these findings demonstrate that a subset of MYBPC3 interacts with RYR2, and that this interaction may be therapeutically exploited to develop CPVT gene therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelMyocytes, CardiacTachycardia, VentricularCarrier ProteinsInduced Pluripotent Stem CellsArrhythmias, CardiacAnimalsHumansMiceDisease Models, AnimalPolymorphic Catecholaminergic Ventricular TachycardiaMyosin Binding Protein CDependovirusGenetic Vectors

Stichwörter der Autor:innen

CPVTMYBPC3RYR2arrhythmiagene therapy

Substanzen

Ryanodine Receptor Calcium Release ChannelCarrier ProteinsMyosin Binding Protein C

Autor:innen und Institutionen

  • Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: fujianlu@fudan.edu.cn.
  • Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: vassilios.bezzerides@cardio.chboston.org.
  • Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: william.pu@cardio.chboston.org.

Förderung

  • NHLBI NIH HHS
  • National Heart Lung and Blood Institute
  • American Heart Association Inc
  • National Institutes of Health
  • Sarepta Therapeutics Inc

Zitieren

APA

Lu, F., Wu, Z., Chi, S., Li, J., Ponek, A., Liou, C., Ma, Q., Bonde, D., Pavlaki, N., Sweat, M. E., Shafaattalab, S., Tharani, Y., Prondzynski, M., Bezzerides, V. J., & Pu, W. T. (2026). An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT. Molecular Therapy, 34(8), 4502-4517. https://doi.org/10.1016/j.ymthe.2026.04.030

Vancouver

Lu F, Wu Z, Chi S, Li J, Ponek A, Liou C, et al. An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT. Molecular Therapy. 2026;34(8):4502-4517. doi:10.1016/j.ymthe.2026.04.030

BibTeX
@article{Lu2026,
  author = {Lu, Fujian and Wu, Zexuan and Chi, Shaopeng and Li, Jiajin and Ponek, Anna and Liou, Carter and Ma, Qing and Bonde, Durgesh and Pavlaki, Nikoleta and Sweat, Mason E and Shafaattalab, Sanam and Tharani, Yashasvi and Prondzynski, Maksymilian and Bezzerides, Vassilios J and Pu, William T},
  title = {An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {8},
  pages = {4502--4517},
  doi = {10.1016/j.ymthe.2026.04.030}
}
Kostenlos starten →